PL1725548T3 - Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy - Google Patents

Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy

Info

Publication number: PL1725548T3
Authority: PL; Poland
Prior art keywords: intermediates; processes; preparation; caspase inhibitors; aspartic
Prior art date: 2004-03-12

Application number

PL05728092T

Other languages

English (en)

Inventor

Gerald J Tanoury

Minzhang Chen

Andrew D Jones

Philip L Nyce

Martin Trudeau

David J Guerin

John R Snoonian

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-12

Filing date

2005-03-11

Publication date

2015-08-31

2005-03-11 Application filed by Vertex Pharma filed Critical Vertex Pharma

2015-08-31 Publication of PL1725548T3 publication Critical patent/PL1725548T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
- C07B43/04—Formation or introduction of functional groups containing nitrogen of amino groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Catalysts (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Pyrrole Compounds (AREA)

PL05728092T 2004-03-12 2005-03-11 Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy PL1725548T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US55248004P	2004-03-12	2004-03-12
PCT/US2005/008251 WO2005090334A2 (en)	2004-03-12	2005-03-11	Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
EP05728092.7A EP1725548B1 (en)	2004-03-12	2005-03-11	Processes and intermediates for the preparation of aspartic acetal caspase inhibitors

Publications (1)

Publication Number	Publication Date
PL1725548T3 true PL1725548T3 (pl)	2015-08-31

Family

ID=34962478

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL05728092T PL1725548T3 (pl)	2004-03-12	2005-03-11	Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy
PL11178126T PL2399915T3 (pl)	2004-03-12	2005-03-11	Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy
PL381358A PL381358A1 (pl)	2004-03-12	2005-03-11	Sposoby i związki pośrednie
PL11178128T PL2399916T3 (pl)	2004-03-12	2005-03-11	Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
PL11178126T PL2399915T3 (pl)	2004-03-12	2005-03-11	Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy
PL381358A PL381358A1 (pl)	2004-03-12	2005-03-11	Sposoby i związki pośrednie
PL11178128T PL2399916T3 (pl)	2004-03-12	2005-03-11	Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy

Country Status (22)

Country	Link
US (4)	US7381827B2 (pl)
EP (3)	EP1725548B1 (pl)
JP (2)	JP4898658B2 (pl)
KR (2)	KR101135765B1 (pl)
CN (3)	CN102225936B (pl)
AR (1)	AR048008A1 (pl)
AU (1)	AU2005223767B2 (pl)
BR (1)	BRPI0508609B8 (pl)
CA (3)	CA2559303C (pl)
DK (3)	DK1725548T3 (pl)
ES (3)	ES2533991T3 (pl)
HK (2)	HK1105955A1 (pl)
HU (1)	HUE024556T2 (pl)
IL (3)	IL178003A (pl)
PL (4)	PL1725548T3 (pl)
PT (3)	PT2399915E (pl)
RU (2)	RU2433127C2 (pl)
SG (2)	SG150547A1 (pl)
SI (3)	SI2399915T1 (pl)
TW (3)	TW201200508A (pl)
WO (1)	WO2005090334A2 (pl)
ZA (1)	ZA200607605B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EE04023B1 (et)	1996-10-18	2003-04-15	Vertex Pharmaceuticals Incorporated	Seriinproteaaside, eriti C-hepatiidi viiruse NS3-proteaasi inhibiitorid
PE20011350A1 (es)	2000-05-19	2002-01-15	Vertex Pharma	PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
AR045596A1 (es)	2003-09-05	2005-11-02	Vertex Pharma	Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
CA2557645C (en) *	2004-02-27	2013-09-24	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
CN1980648A (zh) *	2004-05-15	2007-06-13	沃泰克斯药物股份有限公司	使用ice抑制剂治疗癫痫发作
US8399615B2 (en)	2005-08-19	2013-03-19	Vertex Pharmaceuticals Incorporated	Processes and intermediates
US7964624B1 (en)	2005-08-26	2011-06-21	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
AR055395A1 (es) *	2005-08-26	2007-08-22	Vertex Pharma	Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CN101489557B (zh)	2006-02-27	2013-12-18	弗特克斯药品有限公司	包含vx-950的共晶体和包含所述共晶体的药物组合物
WO2007109080A2 (en)	2006-03-16	2007-09-27	Vertex Pharmaceuticals Incorporated	Deuterated hepatitis c protease inhibitors
EP2099454A4 (en) *	2006-11-17	2010-11-10	Abbott Lab	AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
EP2134717A2 (en)	2007-02-27	2009-12-23	Vertex Pharmceuticals Incorporated	Inhibitors of serine proteases
EP2463284A1 (en) *	2007-02-27	2012-06-13	Vertex Pharmceuticals Incorporated	Co-crystals and pharmaceutical compositions comprising the same
JP5443360B2 (ja)	2007-08-30	2014-03-19	バーテックスファーマシューティカルズインコーポレイテッド	共結晶体およびそれを含む医薬組成物
WO2010017408A1 (en)	2008-08-06	2010-02-11	The Buck Institute For Age Research	Caspase inhibitors and uses thereof
US9113848B2 (en) *	2010-02-03	2015-08-25	Covidien Lp	Surgical retrieval apparatus
JP5769655B2 (ja) *	2012-03-30	2015-08-26	ユニ・チャーム株式会社	吸収性物品
CN103193572B (zh) *	2013-04-07	2015-06-17	山东大学	一种拉唑类化合物单一对映体的分离方法
ES2950100T3 (es)	2016-12-23	2023-10-05	Casp Aid Inc	Inhibición de la caspasa-1 y usos de esta para la prevención y el tratamiento de afecciones neurológicas

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6204261B1 (en)	1995-12-20	2001-03-20	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β Converting enzyme inhibitors
US5874424A (en)	1995-12-20	1999-02-23	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β converting enzyme
GB9123326D0 (en)	1991-11-04	1991-12-18	Sandoz Ltd	Improvements in or relating to organic compounds
BE1008343A3 (nl)	1994-05-06	1996-04-02	Dsm Nv	Bidentaat fosfineligand
US5756466A (en)	1994-06-17	1998-05-26	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1β converting enzyme
US5716929A (en)	1994-06-17	1998-02-10	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1β converting enzyme
US5847135A (en)	1994-06-17	1998-12-08	Vertex Pharmaceuticals, Incorporated	Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) *	1995-06-05	2002-07-16	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β converting enzyme
ATE195923T1 (de) *	1995-11-09	2000-09-15	Akzo Pq Silica Vof	Kompaktiertes natriumsilicat
US5843904A (en) *	1995-12-20	1998-12-01	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1βconverting enzyme
CA2265928A1 (en)	1996-09-12	1998-03-19	Idun Pharmaceuticals, Incorporated	C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
US6200969B1 (en) *	1996-09-12	2001-03-13	Idun Pharmaceuticals, Inc.	Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
EP0929311B8 (en)	1996-09-12	2006-02-01	Idun Pharmaceuticals, Inc.	INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
AU739496B2 (en)	1996-09-12	2001-10-11	Idun Pharmaceuticals, Incorporated	Novel tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes
US5968927A (en) *	1996-09-20	1999-10-19	Idun Pharmaceuticals, Inc.	Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
KR20000049048A (ko)	1996-10-11	2000-07-25	로즈 암스트롱, 크리스틴 에이. 트러트웨인	인터루킨-1β 전환 효소의 아스파르테이트 에스테르 억제제
NZ334906A (en)	1996-10-11	2000-09-29	Basf Ag	A sulphonamido pentanoic acid derivative useful as an interleukin-1-beta converting enzyme inhibitor
US5919790A (en) *	1996-10-11	1999-07-06	Warner-Lambert Company	Hydroxamate inhibitors of interleukin-1β converting enzyme
EE04023B1 (et) *	1996-10-18	2003-04-15	Vertex Pharmaceuticals Incorporated	Seriinproteaaside, eriti C-hepatiidi viiruse NS3-proteaasi inhibiitorid
US6184244B1 (en) *	1996-12-16	2001-02-06	Idun Pharmaceuticals, Inc.	C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
FR2766188B1 (fr)	1997-07-15	2000-02-11	Hoechst Marion Roussel Inc	Nouveau procede de preparation de derives amines d'alkyloxy furanone, composes issus de ce procede et utilisation de ces composes
US6184210B1 (en)	1997-10-10	2001-02-06	Cytovia, Inc.	Dipeptide apoptosis inhibitors and the use thereof
US6054470A (en)	1997-12-18	2000-04-25	Boehringer Ingelheim Pharmaceuticals, Inc.	Src family SH2 domain inhibitors
PT1049703E (pt)	1998-01-20	2003-06-30	Warner Lambert Co	Aldeido do acido n-¬2-(5-benziloxicarbonilamino-6-oxo-2-(4-fluorofenil)-1,6-di-hidro-1-pirimidinil)acetoxil\|-l-aspartico como inibidor da enzima de conversao da interleucina-1beta in vivo
EP2261234A3 (en) *	1998-03-19	2011-04-20	Vertex Pharmaceuticals Incorporated	Inhibitors of caspases
US6197750B1 (en) *	1998-07-02	2001-03-06	Idun Pharmaceuticals, Inc.	C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6323180B1 (en) *	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
US6242422B1 (en) *	1998-10-22	2001-06-05	Idun Pharmacueticals, Inc.	(Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
AU3876600A (en) *	1999-03-16	2000-10-04	Cytovia, Inc.	Substituted 2-aminobenzamide caspase inhibitors and the use thereof
JP2002539193A (ja)	1999-03-16	2002-11-19	メルクフロストカナダアンドカンパニー	カスパーゼ−３阻害薬としてのγ−ケト酸ジペプチド類
AU4213500A (en) *	1999-04-09	2000-11-14	Cytovia, Inc.	Caspase inhibitors and the use thereof
EP1202976B1 (en)	1999-07-19	2006-11-02	Merck Frosst Canada Ltd.	Pyrazinones, compositions containing such compounds
AU6894800A (en) *	1999-08-06	2001-03-05	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
EA200200301A1 (ru)	1999-08-27	2002-08-29	Сайтовиэ, Инк.	ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ
AR026748A1 (es)	1999-12-08	2003-02-26	Vertex Pharma	Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
AU2001249619B2 (en) *	2000-03-29	2006-08-17	Vertex Pharmaceuticals Incorporated	Carbamate caspase inhibitors and uses thereof
PT1268519E (pt) *	2000-04-03	2005-08-31	Vertex Pharma	Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
DE60142470D1 (de) *	2000-04-24	2010-08-12	Vertex Pharma	Verfahren und zwischenprodukte zur herstellung von substituierten asparaginsäure-acetalen
TWI291462B (en)	2000-04-25	2007-12-21	Daiichi Sankyo Co Ltd	Hydrate crystal of neuraminic acid compound
PE20011350A1 (es) *	2000-05-19	2002-01-15	Vertex Pharma	PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US7053057B2 (en)	2000-05-23	2006-05-30	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
CA2409015A1 (en)	2000-06-07	2001-12-13	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
ES2341534T3 (es) *	2000-07-21	2010-06-22	Schering Corporation	Peptidos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
US6800619B2 (en)	2000-09-13	2004-10-05	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
US6846806B2 (en) *	2000-10-23	2005-01-25	Bristol-Myers Squibb Company	Peptide inhibitors of Hepatitis C virus NS3 protein
WO2002042278A2 (en) *	2000-11-21	2002-05-30	Vertex Pharmaceuticals Incorporated	Imidazole and benzimidazole caspase inhibitors and uses thereof
GB0107924D0 (en) *	2001-03-29	2001-05-23	Angeletti P Ist Richerche Bio	Inhibitor of hepatitis C virus NS3 protease
JP4676676B2 (ja)	2001-04-19	2011-04-27	バーテックスファーマシューティカルズインコーポレイテッド	カスパーゼ阻害剤としての複素環ジカルバミド
EP1392289A2 (en)	2001-05-23	2004-03-03	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
ES2279879T3 (es) *	2001-07-11	2007-09-01	Vertex Pharmaceuticals Incorporated	Inhibidores biciclicos puente de la serina proteasa.
WO2003042169A2 (en)	2001-10-09	2003-05-22	Vertex Pharmaceuticals Incorporated	Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof
US7410956B2 (en) *	2002-02-11	2008-08-12	Vertex Pharmaceuticals Incorporated	Caspase inhibitor prodrugs
EP1499898A2 (en)	2002-04-19	2005-01-26	Vertex Pharmaceuticals Incorporated	Regulation of tnf-alpha
US7001899B2 (en)	2002-06-10	2006-02-21	The Procter & Gamble Company	Interleukin converting enzyme inhibitors
US7138395B2 (en) *	2002-06-10	2006-11-21	The Procter & Gamble Company	Interleukin-1β converting enzyme inhibitors
US7041696B2 (en)	2002-06-17	2006-05-09	The Procter & Gamble Company	Interleukin-1β converting enzyme inhibitors
IL165986A0 (en) *	2002-06-28	2006-01-15	Vertex Pharma	Isoquinoline and quinazoline derivatives and pharmaceutical compositions containing the same
TW200500343A (en)	2002-12-20	2005-01-01	Vertex Pharma	Caspase inhibitors and uses thereof
PE20050159A1 (es)	2003-05-27	2005-04-19	Vertex Pharma	Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
CA2557645C (en) *	2004-02-27	2013-09-24	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof

2005
- 2005-03-11 PT PT111781266T patent/PT2399915E/pt unknown
- 2005-03-11 EP EP05728092.7A patent/EP1725548B1/en not_active Expired - Lifetime
- 2005-03-11 ES ES05728092.7T patent/ES2533991T3/es not_active Expired - Lifetime
- 2005-03-11 EP EP11178128.2A patent/EP2399916B1/en not_active Expired - Lifetime
- 2005-03-11 CA CA2559303A patent/CA2559303C/en not_active Expired - Fee Related
- 2005-03-11 PL PL05728092T patent/PL1725548T3/pl unknown
- 2005-03-11 KR KR1020067021136A patent/KR101135765B1/ko active IP Right Grant
- 2005-03-11 BR BRPI0508609A patent/BRPI0508609B8/pt active IP Right Grant
- 2005-03-11 CA CA2768700A patent/CA2768700C/en not_active Expired - Fee Related
- 2005-03-11 WO PCT/US2005/008251 patent/WO2005090334A2/en active Application Filing
- 2005-03-11 AU AU2005223767A patent/AU2005223767B2/en not_active Ceased
- 2005-03-11 DK DK05728092.7T patent/DK1725548T3/en active
- 2005-03-11 KR KR1020117029981A patent/KR20110137409A/ko not_active Application Discontinuation
- 2005-03-11 DK DK11178128T patent/DK2399916T3/en active
- 2005-03-11 PL PL11178126T patent/PL2399915T3/pl unknown
- 2005-03-11 DK DK11178126T patent/DK2399915T3/en active
- 2005-03-11 SG SG200901309-5A patent/SG150547A1/en unknown
- 2005-03-11 ES ES11178126.6T patent/ES2532967T3/es not_active Expired - Lifetime
- 2005-03-11 CN CN2011100999799A patent/CN102225936B/zh not_active Expired - Lifetime
- 2005-03-11 SI SI200531945T patent/SI2399915T1/sl unknown
- 2005-03-11 SI SI200531941T patent/SI2399916T1/sl unknown
- 2005-03-11 PT PT11178128T patent/PT2399916E/pt unknown
- 2005-03-11 HU HUE05728092A patent/HUE024556T2/hu unknown
- 2005-03-11 CA CA2843066A patent/CA2843066C/en not_active Expired - Fee Related
- 2005-03-11 RU RU2006136032/04A patent/RU2433127C2/ru active
- 2005-03-11 ES ES11178128.2T patent/ES2532433T3/es not_active Expired - Lifetime
- 2005-03-11 SI SI200531959T patent/SI1725548T1/sl unknown
- 2005-03-11 JP JP2007503066A patent/JP4898658B2/ja not_active Expired - Lifetime
- 2005-03-11 SG SG200901306-1A patent/SG150546A1/en unknown
- 2005-03-11 AR ARP050100964A patent/AR048008A1/es not_active Application Discontinuation
- 2005-03-11 PL PL381358A patent/PL381358A1/pl not_active Application Discontinuation
- 2005-03-11 PT PT57280927T patent/PT1725548E/pt unknown
- 2005-03-11 US US11/078,147 patent/US7381827B2/en active Active
- 2005-03-11 EP EP11178126.6A patent/EP2399915B1/en not_active Expired - Lifetime
- 2005-03-11 PL PL11178128T patent/PL2399916T3/pl unknown
- 2005-03-11 CN CN2013103410022A patent/CN103467459A/zh active Pending
- 2005-03-11 CN CN2005800144933A patent/CN1950364B/zh not_active Expired - Lifetime
- 2005-03-14 TW TW100133524A patent/TW201200508A/zh unknown
- 2005-03-14 TW TW094107737A patent/TWI398426B/zh not_active IP Right Cessation
- 2005-03-14 TW TW101124668A patent/TWI399356B/zh not_active IP Right Cessation
2006
- 2006-09-11 IL IL178003A patent/IL178003A/en active IP Right Grant
- 2006-09-11 ZA ZA200607605A patent/ZA200607605B/xx unknown
2007
- 2007-10-11 HK HK07111018.8A patent/HK1105955A1/xx not_active IP Right Cessation
2008
- 2008-03-07 US US12/074,983 patent/US7834200B2/en active Active
2010
- 2010-10-12 US US12/902,811 patent/US8293929B2/en not_active Expired - Lifetime
2011
- 2011-07-01 RU RU2011127174/04A patent/RU2011127174A/ru not_active Application Discontinuation
- 2011-10-26 JP JP2011235246A patent/JP2012072151A/ja active Pending
2012
- 2012-03-05 IL IL218488A patent/IL218488A0/en unknown
- 2012-03-05 IL IL218487A patent/IL218487A/en active IP Right Grant
- 2012-04-25 HK HK12104069.4A patent/HK1163672A1/xx not_active IP Right Cessation
- 2012-09-20 US US13/623,563 patent/US20130066083A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TW201200508A (en)	2012-01-01
CA2843066A1 (en)	2005-09-29
SG150547A1 (en)	2009-03-30
CA2768700C (en)	2014-04-29
BRPI0508609B8 (pt)	2021-05-25
RU2433127C2 (ru)	2011-11-10
TWI398426B (zh)	2013-06-11
WO2005090334A2 (en)	2005-09-29
PT2399915E (pt)	2015-03-30
ES2532967T3 (es)	2015-04-06
US8293929B2 (en)	2012-10-23
IL218488A0 (en)	2012-04-30
AU2005223767A1 (en)	2005-09-29
US20130066083A1 (en)	2013-03-14
CA2768700A1 (en)	2005-09-29
CA2559303A1 (en)	2005-09-29
SI1725548T1 (sl)	2015-05-29
SI2399916T1 (sl)	2015-05-29
KR20070006835A (ko)	2007-01-11
ES2532433T3 (es)	2015-03-26
PL2399915T3 (pl)	2015-07-31
PL2399916T3 (pl)	2015-06-30
SG150546A1 (en)	2009-03-30
BRPI0508609A (pt)	2007-07-31
DK1725548T3 (en)	2015-03-23
IL218487A (en)	2015-08-31
CN1950364B (zh)	2011-06-08
PL381358A1 (pl)	2007-05-28
JP2007528904A (ja)	2007-10-18
CN102225936A (zh)	2011-10-26
US20110071298A1 (en)	2011-03-24
TW201247594A (en)	2012-12-01
IL178003A0 (en)	2006-12-31
RU2011127174A (ru)	2013-01-10
PT2399916E (pt)	2015-03-17
TW200602341A (en)	2006-01-16
HK1163672A1 (en)	2012-09-14
US7834200B2 (en)	2010-11-16
AR048008A1 (es)	2006-03-15
US20090048429A1 (en)	2009-02-19
CN102225936B (zh)	2013-09-11
IL178003A (en)	2012-04-30
WO2005090334A3 (en)	2005-11-17
JP2012072151A (ja)	2012-04-12
KR101135765B1 (ko)	2012-04-23
EP1725548B1 (en)	2015-01-14
AU2005223767B2 (en)	2011-12-01
HUE024556T2 (hu)	2016-02-29
EP2399916B1 (en)	2014-12-10
BRPI0508609B1 (pt)	2021-03-30
CA2843066C (en)	2016-06-07
EP2399916A1 (en)	2011-12-28
HK1105955A1 (en)	2008-02-29
IL218487A0 (en)	2012-04-30
EP2399915B1 (en)	2014-12-17
PT1725548E (pt)	2015-04-16
US20060020016A1 (en)	2006-01-26
DK2399915T3 (en)	2015-03-09
JP4898658B2 (ja)	2012-03-21
CA2559303C (en)	2013-09-10
DK2399916T3 (en)	2015-03-02
ZA200607605B (en)	2009-04-29
EP2399915A1 (en)	2011-12-28
TWI399356B (zh)	2013-06-21
ES2533991T3 (es)	2015-04-16
EP1725548A2 (en)	2006-11-29
RU2006136032A (ru)	2008-04-20
SI2399915T1 (sl)	2015-05-29
KR20110137409A (ko)	2011-12-22
US7381827B2 (en)	2008-06-03
CN1950364A (zh)	2007-04-18
CN103467459A (zh)	2013-12-25

Publication	Publication Date	Title
ZA200607605B (en)	2009-04-29	Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
IL182305A0 (en)	2007-07-24	Diaminoalkane aspartic protease inhibitors
ITMI20032121A1 (it)	2005-05-05	Procedimento per la preparazione di imiquimod e suoi intermedi
GB2428296B (en)	2007-09-26	Enhancing the acqisition and processing of low frequencies for sub-salt imaging
ZA200711085B (en)	2009-09-30	Processes for the manufacture of rosuvastatin and intermediates
IL187303A0 (en)	2008-04-13	Methods of prepering 3 - cyano - quinolines and intermediates made thereby
ZA200710342B (en)	2008-12-31	The preparation and use of compounds as aspartyl protease inhibitors
IL213843A0 (en)	2011-07-31	4-aminotetracyclines and methods of use thereof
IL176958A0 (en)	2006-12-10	Compounds and methods of use
IL180359A0 (en)	2007-06-03	Solid forms of linezolid and processes for preparation thereof
EP1856006A4 (en)	2011-04-20	SIALON CERAMIC AND METHOD OF MANUFACTURE
HK1099757A1 (en)	2007-08-24	Caspase inhibitors and uses thereof
IL190201A0 (en)	2008-11-03	Pde inhibitors and combinations thereof for the treatment of urological disorders
AP2006003753A0 (en)	2006-10-31	Detection of diamonds
PL1817387T3 (pl)	2010-12-31	Zastosowanie polisilazanów do nakładania powłok na taśmy metalowe
ZA200705773B (en)	2009-01-28	Thermocouple assembly and method of use
EP1812451A4 (en)	2009-10-21	COMPOUNDS AND METHODS OF USE THEREOF
IL187832A0 (en)	2008-03-20	Methods and intermediates for the preparation of optionally radio- labeled imatinib
GB0414120D0 (en)	2004-07-28	Novel processes and intermediates
SG115828A1 (en)	2005-10-28	Fluid-ejection device and methods of forming same
GB0504333D0 (en)	2005-04-06	Treatment of cytokine dysregulation
ZA200802668B (en)	2009-09-30	PDE inhibitors and combinations thereof for the treatment of urological disorders
ITMI20041141A1 (it)	2004-09-07	Dispositivo e metodo per la preparazione di brodi e bevande
ZA200705455B (en)	2008-11-26	Silicon compounds and their use
ITBO20040106A1 (it)	2004-05-24	Complesso di elementi per la definizione di servizi igienici mobili